Drugs / NOV-002
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT00499122 | Jun 2007 → Apr 2011 | breast cancer | University of Miami | Completed | Met primary |
| Phase 2 | NCT00345540 | Jul 2006 → May 2008 | ovarian cancer | Cellectar Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00960726 | — | leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00347412 | Nov 2006 → Jan 2010 | non-small cell lung carcinoma | Cellectar Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NOV-002 | “NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and metastasis and enhances anti-tumor immune...” PMID 22138748 ↗ Dec 2011 |
| Route | Intravenous | “NOV-002 is given by IV bolus” NCT00345540 ↗ |